StockMacro
Company, fund or insider

Help

Menu

Harmony Biosciences

$32.59 +8.3% in 6 monthsMarket cap $1.9B

HRMY on XNAS, Health Care, Harmony Biosciences Holdings, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue rose 20% to $989.4M while short interest rose 23% on the prior report to 11% of shares.

  • GoodLatest quarter revenue rose 12% to $268.9M from a year earlier
  • BadNet income fell 3.8% to $178.6M over the last 12 months

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Industry
Pharmaceutical preparations (Health Care)
Employees
293
Website
harmonybiosciences.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $268.9M, net income $48.2M.
Quarter to 31 Dec 2021: revenue $91.2M, net income $22.7MQuarter to 31 Dec 2021: revenue $91.2M, net income $22.7MQuarter to 31 Mar 2022: revenue $85.3M, net income $21.5MQuarter to 31 Mar 2022: revenue $85.3M, net income $21.5MQuarter to 30 Jun 2022: revenue $107.0M, net income $23.5MQuarter to 30 Jun 2022: revenue $107.0M, net income $23.5MQuarter to 30 Sep 2022: revenue $117.2M, net income $87.9MQuarter to 30 Sep 2022: revenue $117.2M, net income $87.9MQuarter to 31 Dec 2022: revenue $128.3M, net income $48.5MQuarter to 31 Dec 2022: revenue $128.3M, net income $48.5MQuarter to 31 Mar 2023: revenue $119.1M, net income $29.5MQuarter to 31 Mar 2023: revenue $119.1M, net income $29.5MQuarter to 30 Jun 2023: revenue $134.2M, net income $34.3MQuarter to 30 Jun 2023: revenue $134.2M, net income $34.3MQuarter to 30 Sep 2023: revenue $160.3M, net income $38.5MQuarter to 30 Sep 2023: revenue $160.3M, net income $38.5MQuarter to 31 Dec 2023: revenue $168.4M, net income $26.6MQuarter to 31 Dec 2023: revenue $168.4M, net income $26.6MQuarter to 31 Mar 2024: revenue $154.6M, net income $38.3MQuarter to 31 Mar 2024: revenue $154.6M, net income $38.3MQuarter to 30 Jun 2024: revenue $172.8M, net income $11.6MQuarter to 30 Jun 2024: revenue $172.8M, net income $11.6MQuarter to 30 Sep 2024: revenue $186.0M, net income $46.1MQuarter to 30 Sep 2024: revenue $186.0M, net income $46.1MQuarter to 31 Dec 2024: revenue $201.3M, net income $49.5MQuarter to 31 Dec 2024: revenue $201.3M, net income $49.5MQuarter to 31 Mar 2025: revenue $184.7M, net income $45.6MQuarter to 31 Mar 2025: revenue $184.7M, net income $45.6MQuarter to 30 Jun 2025: revenue $200.5M, net income $39.8MQuarter to 30 Jun 2025: revenue $200.5M, net income $39.8MQuarter to 30 Sep 2025: revenue $239.5M, net income $50.9MQuarter to 30 Sep 2025: revenue $239.5M, net income $50.9MQuarter to 31 Dec 2025: revenue $243.8M, net income $22.5MQuarter to 31 Dec 2025: revenue $243.8M, net income $22.5MQuarter to 31 Mar 2026: revenue $215.4M, net income $32.5MQuarter to 31 Mar 2026: revenue $215.4M, net income $32.5MQuarter to 30 Jun 2026: revenue $261.3M, net income $75.4MQuarter to 30 Jun 2026: revenue $261.3M, net income $75.4MQuarter to 30 Sep 2026: revenue $268.9M, net income $48.2MQuarter to 30 Sep 2026: revenue $268.9M, net income $48.2M
31 Dec 2021RevenueNet incometallest bar $268.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$268.9M$48.2M
30 Jun 2026$261.3M$75.4M
31 Mar 2026$215.4M$32.5M
31 Dec 2025$243.8M$22.5M
30 Sep 2025$239.5M$50.9M
30 Jun 2025$200.5M$39.8M
31 Mar 2025$184.7M$45.6M
31 Dec 2024$201.3M$49.5M
30 Sep 2024$186.0M$46.1M
30 Jun 2024$172.8M$11.6M
31 Mar 2024$154.6M$38.3M
31 Dec 2023$168.4M$26.6M
30 Sep 2023$160.3M$38.5M
30 Jun 2023$134.2M$34.3M
31 Mar 2023$119.1M$29.5M
31 Dec 2022$128.3M$48.5M
30 Sep 2022$117.2M$87.9M
30 Jun 2022$107.0M$23.5M
31 Mar 2022$85.3M$21.5M
31 Dec 2021$91.2M$22.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $989.4M $825.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +20% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $178.6M $185.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $3.03 $3.18
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 74.0% 77.7% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 22.2% 27.3% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 18.1% 22.5% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 18.7% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $771.1M $672.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $149.1M $168.5M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$622.0M (net cash) -$504.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.14 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $18.26
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 10.7 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.9 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.3 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.8 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Harmony BiosciencesHRMY (this company) $1.9B10.71.9+20%18.1%
Trevi TherapeuticsTRVI $1.9Bloss–––
BiohavenBHVN $1.9Bloss–––
Aurinia PharmaceuticalsAUPH $2.0B6.36.1+21%97.7%
ImmunomeIMNM $1.9Bloss–––
Vera TherapeuticsVERA $1.8Bloss–––

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+12%

$268.9M vs $239.5M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$3.1M

bought $0, sold $3.1M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+11%

353 13F filers vs 318

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

96%

56.6M shares held by 13F filers (30 Sep 2026) of 58.7M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

11%

6.7M shares sold short (30 Oct 2026) of 58.7M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.6

6.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+23%

5.4M shares sold short in the report before, 6.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

60%

60% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$760K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

11 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 61, 1.5× a year earlier

Price $32.59 on 20 Nov 2026, -2.4% over 12 months (12-month range $26.54 to $42.86)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $5.8M in the last 12 months (the 12 months before: -$5.5M).
Revenue per quarter. Revenue $268.9M in the latest quarter, +12% on a year earlier.
Capital spending per quarter. Capital spending $107K in the latest quarter, -79% on a year earlier.
Institutional holders (13F filers). 353 13F filers reported holding it in the latest 13F quarter, +27% on a year earlier.
Lobbying spend. Lobbying spend: $760K published in the last 12 months, +13% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 61 vs usual 36 (2026-09-30); 1.5x the same period a year earlier
13 Oct 20268-K and other filingsDirector or officer change
16 Jul 20268-K and other filingsDirector or officer change
16 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 May 2026Lobbying filinglobbying engagement terminated (HARPER & BAILEY GOVERNMENTAL SOLUTIONS LLC)
14 Apr 2026Sharp changeShort interest spike: short interest spike, 7.6M vs usual 4.3M (2026-03-31); 2.2x the same period a year earlier
14 Apr 20268-K and other filingsDirector or officer change
2 Apr 20268-K and other filingsDirector or officer change
2 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Mar 2026Sharp changeShort interest spike: short interest spike, 7.6M vs usual 4.3M (2026-03-13); 1.9x the same period a year earlier
17 Mar 2026Sharp changeShort interest spike: short interest spike, 7.9M vs usual 4.2M (2026-02-27); 2.0x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 6.0M vs usual 4.1M (2026-01-15); 1.1x the same period a year earlier
20 Jan 2026Sharp changeLobbying spend jump: lobbying spend jump, 220K vs usual 150K (2025-12-31); 1.5x the same period a year earlier
20 Jan 2026Lobbying filinglobbying engagement terminated (SCHAERR JAFFE LLP)
25 Jul 2025Lobbying filingnew lobbying registration (SCHAERR JAFFE LLP)
16 Jul 2025Lobbying filingnew lobbying registration (LMH STRATEGIC SOLUTIONS)
3 Apr 20258-K and other filingsDirector or officer change
24 Mar 20258-K and other filingsDirector or officer change
24 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Dec 2024Lobbying filinglobbying engagement terminated (WATKINS & EAGER PLLC)
5 Dec 2024Lobbying filingnew lobbying registration (HARPER & BAILEY GOVERNMENTAL SOLUTIONS LLC)
1 Jul 20248-K and other filingsDirector or officer change
3 May 20248-K and other filingsDirector or officer change
3 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Apr 2024Sharp changeLobbying on a new issue: lobbying on a new issue: INS, MMM (2024-03-31)
8 Apr 2024Lobbying filinglobbying engagement terminated (THORN RUN PARTNERS)
19 Jan 2024Lobbying filinglobbying engagement terminated (RAMPY NORTHRUP LLC)
12 Jan 2024Lobbying filingnew lobbying registration (WATKINS & EAGER PLLC)
8 Jan 2024Lobbying filinglobbying engagement terminated (WATKINS & EAGER PLLC)
8 Nov 20238-K and other filingsDirector or officer change
11 Oct 20238-K and other filingsCompleted an acquisition or asset sale
5 Oct 20238-K and other filingsDirector or officer change
5 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Jul 20238-K and other filingsA major agreement ended
24 Apr 20238-K and other filingsDirector or officer change
24 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Jan 20238-K and other filingsDirector or officer change
6 Jan 20238-K and other filingsDirector or officer change
6 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Apr 2022Sharp changeShort interest spike: short interest spike, 3.6M vs usual 1.1M (2022-03-31); 5.5x the same period a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 3.6M vs usual 1.0M (2022-03-15); 5.8x the same period a year earlier
15 Mar 2022Sharp changeShort interest spike: short interest spike, 3.3M vs usual 951K (2022-02-28); 5.7x the same period a year earlier
1 Mar 2022Sharp changeShort interest spike: short interest spike, 3.3M vs usual 923K (2022-02-15); 6.9x the same period a year earlier
15 Feb 2022Sharp changeShort interest spike: short interest spike, 3.0M vs usual 914K (2022-01-31); 6.0x the same period a year earlier
1 Feb 2022Sharp changeShort interest spike: short interest spike, 3.3M vs usual 828K (2022-01-14); 4.9x the same period a year earlier
28 Dec 2021Sharp changeShort interest spike: short interest spike, 3.1M vs usual 813K (2021-12-15); 3.5x the same period a year earlier
14 Dec 2021Sharp changeShort interest spike: short interest spike, 3.2M vs usual 755K (2021-11-30); 4.2x the same period a year earlier
30 Nov 2021Sharp changeShort interest spike: short interest spike, 2.6M vs usual 731K (2021-11-15); 3.7x the same period a year earlier
Insider net buying (open market)
Month from 1 Dec 2021: -$2.1M published
Month from 1 Jan 2022: -$1.5M published
Month from 1 Feb 2022: -$341K published
Month from 1 Mar 2022: -$47.9M published
Month from 1 Apr 2022: -$17.6M published
Month from 1 Jun 2022: -$7.0M published
Month from 1 Jul 2022: -$20.5M published
Month from 1 Aug 2022: -$55.7M published
Month from 1 Oct 2022: -$544K published
Month from 1 Nov 2022: -$60.0M published
Month from 1 Dec 2022: -$23.3M published
Month from 1 Mar 2024: -$390K published
Month from 1 Oct 2024: -$2.7M published
Month from 1 Nov 2024: -$279.6M published
Month from 1 Jan 2025: -$4.2M published
Month from 1 Mar 2025: -$159K published
Month from 1 Apr 2025: -$227K published
Month from 1 Aug 2025: -$787K published
Month from 1 Nov 2025: -$120K published
Month from 1 Dec 2025: -$1.8M published
Month from 1 Jan 2026: -$892K published
Month from 1 Sep 2026: -$3.1M published
Revenue per quarter
Quarter ended 31 Dec 2021: $91.2M, +62% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $85.3M, +43% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $107.0M, +45% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $117.2M, +45% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $128.3M, +41% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $119.1M, +40% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $134.2M, +25% on a year earlier; public on 2 Aug 2023
Quarter ended 30 Sep 2023: $160.3M, +37% on a year earlier; public on 1 Nov 2023
Quarter ended 31 Dec 2023: $168.4M, +31% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $154.6M, +30% on a year earlier; public on 1 May 2024
Quarter ended 30 Jun 2024: $172.8M, +29% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $186.0M, +16% on a year earlier; public on 30 Oct 2024
Quarter ended 31 Dec 2024: $201.3M, +20% on a year earlier; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $184.7M, +19% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $200.5M, +16% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $239.5M, +29% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $243.8M, +21% on a year earlier; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $215.4M, +17% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $261.3M, +30% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $268.9M, +12% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $45K, +1025% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $41K, -80% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $86K, -7.5% on a year earlier; public on 2 Nov 2022
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 1 Nov 2023
Quarter ended 31 Dec 2023: $107K; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $5K; public on 1 May 2024
Quarter ended 30 Jun 2024: $632K; public on 7 Aug 2024
Quarter ended 31 Dec 2024: $513K, +379% on a year earlier; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $128K, +2460% on a year earlier; public on 7 May 2025
Quarter ended 30 Sep 2025: $71K; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $107K, -79% on a year earlier; public on 25 Feb 2026
Institutional holders (13F filers)
31 Dec 2021 report: 132; public on 14 Feb 2022
31 Mar 2022 report: 172; public on 16 May 2022
30 Jun 2022 report: 172; public on 15 Aug 2022
30 Sep 2022 report: 186; public on 14 Nov 2022
31 Dec 2022 report: 220; public on 14 Feb 2023
31 Mar 2023 report: 202; public on 15 May 2023
30 Jun 2023 report: 193; public on 14 Aug 2023
30 Sep 2023 report: 185; public on 14 Nov 2023
31 Dec 2023 report: 211; public on 14 Feb 2024
31 Mar 2024 report: 197; public on 15 May 2024
30 Jun 2024 report: 206; public on 14 Aug 2024
30 Sep 2024 report: 224; public on 14 Nov 2024
31 Dec 2024 report: 242; public on 14 Feb 2025
31 Mar 2025 report: 256; public on 15 May 2025
30 Jun 2025 report: 266; public on 14 Aug 2025
30 Sep 2025 report: 279; public on 14 Nov 2025
31 Dec 2025 report: 306; public on 17 Feb 2026
31 Mar 2026 report: 300; public on 15 May 2026
30 Jun 2026 report: 318; public on 14 Aug 2026
30 Sep 2026 report: 353; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $280K published
Quarter from 1 Apr 2022: $280K published
Quarter from 1 Jul 2022: $270K published
Quarter from 1 Oct 2022: $265K published
Quarter from 1 Jan 2023: $265K published
Quarter from 1 Apr 2023: $265K published
Quarter from 1 Jul 2023: $295K published
Quarter from 1 Oct 2023: $295K published
Quarter from 1 Jan 2024: $175K published
Quarter from 1 Apr 2024: $170K published
Quarter from 1 Jul 2024: $150K published
Quarter from 1 Oct 2024: $150K published
Quarter from 1 Jan 2025: $150K published
Quarter from 1 Apr 2025: $150K published
Quarter from 1 Jul 2025: $150K published
Quarter from 1 Oct 2025: $220K published
Quarter from 1 Jan 2026: $220K published
Quarter from 1 Apr 2026: $180K published
Quarter from 1 Jul 2026: $180K published
Quarter from 1 Oct 2026: $180K published

What is unusual now

  • Made public in the last 90 days: it saw 61 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year.
  • Many funds opening a new position: saw 61 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year Public on 16 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $5.8M in the last 12 months (the 12 months before: -$5.5M).
  • Revenue per quarter: Revenue $268.9M in the latest quarter, +12% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 92 insider trades

Last 90 days: 2 sales, $3.1M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Sep 2026Kumar BudurCHIEF MEDICAL OFFICERSellafter exercising options38,452$43.05$1.7MForm 4
9 Sep 2026Kumar BudurCHIEF MEDICAL OFFICERSellafter exercising options33,954$42.80$1.5MForm 4
28 Jan 2026Sandip KapadiaCHIEF FINANCIAL OFFICERSellplanned in advance (10b5-1)3,746$37.15$139KForm 4
20 Jan 2026Sandip KapadiaCHIEF FINANCIAL OFFICERSellplanned in advance (10b5-1)20,961$35.92$753KForm 4
17 Dec 2025Jeffrey M. DaynoPRESIDENT, CEOSellplanned in advance (10b5-1); after exercising options25,933$40.11$1.0MForm 4
9 Dec 2025Sandip KapadiaCHIEF FINANCIAL OFFICERSellplanned in advance (10b5-1); after exercising options20,000$39.54$791KForm 4
25 Nov 2025Sandip KapadiaCHIEF FINANCIAL OFFICERSellplanned in advance (10b5-1)3,427$35.00$120KForm 4
19 Aug 2025Sandip KapadiaCHIEF FINANCIAL OFFICERSellplanned in advance (10b5-1)21,573$36.50$787KForm 4

353 institutions reported shares at the end of Q3 2026, 96% of the shares outstanding; 61 opened a position, 29 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.7.9M13.5%$311.3M+827K+12%
FMR LLC (Fidelity)3.3M5.57%$128.3M-305K-8.5%
American Century Companies Inc3.1M5.30%$122.2M+574K+23%
Vanguard Portfolio Management LLC3.0M5.06%$116.6M+88K+3.1%
Dimensional Fund Advisors LP2.6M4.51%$104.0M+256K+11%
Vanguard Capital Management LLC2.2M3.76%$86.7M+103K+4.9%
LSV Asset Management2.2M3.75%+144K+7.0%
State Street Corp2.1M3.63%$83.6M+271K+15%
Geode Capital Management, LLC1.5M2.64%$60.8M+107K+7.4%
Armistice Capital, LLC1.4M2.45%$56.4M-128K-8.2%

Company events

All 28 company events

In 12 months: 4 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
13 Oct 2026Director or officer change8-K
16 Jul 2026Director or officer change8-K
14 Apr 2026Director or officer change8-K
2 Apr 2026Director or officer change8-K
3 Apr 2025Director or officer change8-K
24 Mar 2025Director or officer change8-K
1 Jul 2024Director or officer change8-K
3 May 2024Director or officer change8-K

Reported lobbying spend: $180K in Q3 2026, $180K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Jan 2026EndedHarper & Bailey Governmental Solutions LLCfor Harmony BiosciencesProducing meeting materials; Assisting in meetings to secure support at federal level and awareness to policymakers.Health issuesFiling
31 Dec 2025EndedSchaerr Jaffe LLPfor Harmony Biosciences Management, Inc.Orphan drug manufacturing and distributionHealth issuesFiling
1 Jul 2025NewSchaerr Jaffe LLPfor Harmony Biosciences Management, Inc.Issues related to orphan drug manufacturing and distribution.Health issuesFiling
1 Jul 2025NewLMH Strategic Solutionsfor Harmony BiosciencesPrescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.Pharmacy, Medicare/MedicaidFiling
1 Nov 2024NewHarper & Bailey Governmental Solutions LLCfor Harmony BiosciencesProducing meeting materials; Assisting in meetings to secure support at federal level and awareness to policymakers.Health issuesFiling
31 Oct 2024EndedWatkins & Eager PLLCfor Harmony BiosciencesProducing meeting materials; Assisting in meetings to secure support at federal level and awareness to policymakers.Health issuesFiling
1 Jan 2024NewWatkins & Eager PLLCfor Harmony BiosciencesSeek help in Congress & FDA to get FDA approval for Zygel to help those individuals living with Fragile X Syndrome.Government issues, PharmacyFiling
31 Dec 2023EndedThorn Run Partnersfor Harmony BiosciencesIssues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350 - Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.18Health issuesFiling

The 5 newest of 146 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

3 Feb 2026confirmed

Confirmed across sources Lobbying and Short interest and volume

Harmony Biosciences (HRMY): reported $220K of lobbying spend for the quarter ended 31 Dec 2025, 1.5× the same quarter last year, while it had 6.0M shares sold short in the 15 Jan 2026 report, 1.1× the same report last year. Two unrelated kinds of activity within 14 days.

  • Lobbying: Lobbying spend jump, became public on 20 Jan 2026
  • Short interest and volume: Short interest spike, became public on 28 Jan 2026
2023-12-31: $175K2024-03-31: $170K2024-06-30: $150K2024-09-30: $150K2024-12-31: $150K2025-03-31: $150K2025-06-30: $150K2025-09-30: $220K2025-12-31: $220K
The quarter ended 31 Dec 2025 against the 8 quarters before it. this quarterearliernormal: $150K
See the evidence (2 changes)

Lobbying: Lobbying spend jump became public on 20 Jan 2026

Harmony Biosciences reported $220K of lobbying spend for the quarter ended 31 Dec 2025, 1.5× the same quarter last year.

This period
$220K (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$150K
Typical spread (median absolute deviation)
$0
How far from its usual level
+3.5
Same quarter last year
$150K
History used
3,928 days
2023-12-31: $175K2024-03-31: $170K2024-06-30: $150K2024-09-30: $150K2024-12-31: $150K2025-03-31: $150K2025-06-30: $150K2025-09-30: $220K2025-12-31: $220K
the quarter ended 31 Dec 20258 earlier quartersnormal: $150K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Short interest and volume: Short interest spike became public on 28 Jan 2026

Harmony Biosciences had 6.0M shares sold short in the 15 Jan 2026 report, 1.1× the same report last year.

This period
6.0M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
4.1M
Typical spread (median absolute deviation)
324K
How far from its usual level
+3.9
Same report last year
5.5M
History used
1,963 days
2025-01-15: 5.5M2025-01-31: 3.8M2025-02-14: 3.7M2025-02-28: 3.9M2025-03-14: 4.1M2025-03-31: 3.5M2025-04-15: 3.3M2025-04-30: 3.2M2025-05-15: 2.6M2025-05-30: 3.4M2025-06-13: 3.7M2025-06-30: 4.4M2025-07-15: 4.4M2025-07-31: 4.2M2025-08-15: 4.3M2025-08-29: 4.3M2025-09-15: 4.2M2025-09-30: 3.2M2025-10-15: 3.7M2025-10-31: 4.1M2025-11-14: 4.3M2025-11-28: 4.4M2025-12-15: 4.3M2025-12-31: 4.4M2026-01-15: 6.0M
the 15 Jan 2026 report24 earlier reportsnormal: 4.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

26 Oct 2021confirmed

Confirmed across sources Lobbying and Short interest and volume

Harmony Biosciences (HRMY): reported $295K of lobbying spend for the quarter ended 30 Sep 2021, 2.1× the same quarter last year, while it had 3.2M shares sold short in the 30 Nov 2021 report, 4.2× the same report last year. Two unrelated kinds of activity within 70 days.

  • Short interest and volume: Short interest spike, became public on 13 Oct 2021
  • Lobbying: Lobbying spend jump, became public on 19 Oct 2021
  • Short interest and volume: Short interest spike, became public on 10 Nov 2021
  • Short interest and volume: Short interest spike, became public on 25 Nov 2021
  • Short interest and volume: Short interest spike, became public on 10 Dec 2021
  • Short interest and volume: Short interest spike, became public on 28 Dec 2021
2019-09-30: $160K2019-12-31: $160K2020-03-31: $160K2020-06-30: $140K2020-09-30: $140K2020-12-31: $185K2021-03-31: $275K2021-06-30: $295K2021-09-30: $295K
The quarter ended 30 Sep 2021 against the 8 quarters before it. this quarterearliernormal: $160K
See the evidence (6 changes)

Short interest and volume: Short interest spike became public on 13 Oct 2021

Harmony Biosciences had 1.4M shares sold short in the 30 Sep 2021 report, 2.2× the same report last year.

This period
1.4M (the 30 Sep 2021 report)
Normal report (median of 24 earlier)
655K
Typical spread (median absolute deviation)
135K
How far from its usual level
+3.7
Same report last year
647K
History used
395 days
2020-09-30: 647K2020-10-15: 315K2020-10-30: 645K2020-11-13: 715K2020-11-30: 763K2020-12-15: 880K2020-12-31: 747K2021-01-15: 674K2021-01-29: 490K2021-02-12: 474K2021-02-26: 584K2021-03-15: 617K2021-03-31: 663K2021-04-15: 304K2021-04-30: 492K2021-05-14: 592K2021-05-28: 638K2021-06-15: 598K2021-06-30: 920K2021-07-15: 909K2021-07-30: 1.1M2021-08-13: 1.1M2021-08-31: 975K2021-09-15: 927K2021-09-30: 1.4M
the 30 Sep 2021 report24 earlier reportsnormal: 655K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying spend jump became public on 19 Oct 2021

Harmony Biosciences reported $295K of lobbying spend for the quarter ended 30 Sep 2021, 2.1× the same quarter last year.

This period
$295K (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$160K
Typical spread (median absolute deviation)
$20K
How far from its usual level
+4.6
Same quarter last year
$140K
History used
2,375 days
2019-09-30: $160K2019-12-31: $160K2020-03-31: $160K2020-06-30: $140K2020-09-30: $140K2020-12-31: $185K2021-03-31: $275K2021-06-30: $295K2021-09-30: $295K
the quarter ended 30 Sep 20218 earlier quartersnormal: $160K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Short interest and volume: Short interest spike became public on 10 Nov 2021

Harmony Biosciences had 2.6M shares sold short in the 29 Oct 2021 report, 4.0× the same report last year.

This period
2.6M (the 29 Oct 2021 report)
Normal report (median of 24 earlier)
695K
Typical spread (median absolute deviation)
194K
How far from its usual level
+6.5
Same report last year
645K
History used
424 days
2020-10-30: 645K2020-11-13: 715K2020-11-30: 763K2020-12-15: 880K2020-12-31: 747K2021-01-15: 674K2021-01-29: 490K2021-02-12: 474K2021-02-26: 584K2021-03-15: 617K2021-03-31: 663K2021-04-15: 304K2021-04-30: 492K2021-05-14: 592K2021-05-28: 638K2021-06-15: 598K2021-06-30: 920K2021-07-15: 909K2021-07-30: 1.1M2021-08-13: 1.1M2021-08-31: 975K2021-09-15: 927K2021-09-30: 1.4M2021-10-15: 1.3M2021-10-29: 2.6M
the 29 Oct 2021 report24 earlier reportsnormal: 695K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Nov 2021

Harmony Biosciences had 2.6M shares sold short in the 15 Nov 2021 report, 3.7× the same report last year.

This period
2.6M (the 15 Nov 2021 report)
Normal report (median of 24 earlier)
731K
Typical spread (median absolute deviation)
183K
How far from its usual level
+7.0
Same report last year
715K
History used
441 days
2020-11-13: 715K2020-11-30: 763K2020-12-15: 880K2020-12-31: 747K2021-01-15: 674K2021-01-29: 490K2021-02-12: 474K2021-02-26: 584K2021-03-15: 617K2021-03-31: 663K2021-04-15: 304K2021-04-30: 492K2021-05-14: 592K2021-05-28: 638K2021-06-15: 598K2021-06-30: 920K2021-07-15: 909K2021-07-30: 1.1M2021-08-13: 1.1M2021-08-31: 975K2021-09-15: 927K2021-09-30: 1.4M2021-10-15: 1.3M2021-10-29: 2.6M2021-11-15: 2.6M
the 15 Nov 2021 report24 earlier reportsnormal: 731K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Dec 2021

Harmony Biosciences had 3.2M shares sold short in the 30 Nov 2021 report, 4.2× the same report last year.

This period
3.2M (the 30 Nov 2021 report)
Normal report (median of 24 earlier)
755K
Typical spread (median absolute deviation)
171K
How far from its usual level
+9.7
Same report last year
763K
History used
456 days
2020-11-30: 763K2020-12-15: 880K2020-12-31: 747K2021-01-15: 674K2021-01-29: 490K2021-02-12: 474K2021-02-26: 584K2021-03-15: 617K2021-03-31: 663K2021-04-15: 304K2021-04-30: 492K2021-05-14: 592K2021-05-28: 638K2021-06-15: 598K2021-06-30: 920K2021-07-15: 909K2021-07-30: 1.1M2021-08-13: 1.1M2021-08-31: 975K2021-09-15: 927K2021-09-30: 1.4M2021-10-15: 1.3M2021-10-29: 2.6M2021-11-15: 2.6M2021-11-30: 3.2M
the 30 Nov 2021 report24 earlier reportsnormal: 755K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Dec 2021

Harmony Biosciences had 3.1M shares sold short in the 15 Dec 2021 report, 3.5× the same report last year.

This period
3.1M (the 15 Dec 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
225K
How far from its usual level
+6.7
Same report last year
880K
History used
471 days
2020-12-15: 880K2020-12-31: 747K2021-01-15: 674K2021-01-29: 490K2021-02-12: 474K2021-02-26: 584K2021-03-15: 617K2021-03-31: 663K2021-04-15: 304K2021-04-30: 492K2021-05-14: 592K2021-05-28: 638K2021-06-15: 598K2021-06-30: 920K2021-07-15: 909K2021-07-30: 1.1M2021-08-13: 1.1M2021-08-31: 975K2021-09-15: 927K2021-09-30: 1.4M2021-10-15: 1.3M2021-10-29: 2.6M2021-11-15: 2.6M2021-11-30: 3.2M2021-12-15: 3.1M
the 15 Dec 2021 report24 earlier reportsnormal: 813K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Institutional holdings change

    saw 61 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year.

    Same quarter last year: 40; its normal quarter is 36.

    See the evidence
    This period
    61 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    36
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +4.2
    Same quarter last year
    40
    History used
    2,191 days
    2024-09-30: 322024-12-31: 292025-03-31: 352025-06-30: 372025-09-30: 402025-12-31: 432026-03-31: 342026-06-30: 472026-09-30: 61
    the quarter ended 30 Sep 20268 earlier quartersnormal: 36

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 13 Oct 2026Filings record

    Director or officer change

  3. 16 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 16 Jul 2026Filings record

    Director or officer change

  5. 4 May 2026Lobbying record

    HARMONY BIOSCIENCES: lobbying engagement terminated (HARPER & BAILEY GOVERNMENTAL SOLUTIONS LLC) (dated 31 Jan 2026)

  6. 14 Apr 2026Filings record

    Director or officer change

  7. 11 Apr 2026Short interest and volume change

    had 7.6M shares sold short in the 31 Mar 2026 report, 2.2× the same report last year.

    Same report last year: 3.5M; its normal report is 4.3M.

    See the evidence
    This period
    7.6M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    4.3M
    Typical spread (median absolute deviation)
    561K
    How far from its usual level
    +4.1
    Same report last year
    3.5M
    History used
    2,038 days
    2025-03-31: 3.5M2025-04-15: 3.3M2025-04-30: 3.2M2025-05-15: 2.6M2025-05-30: 3.4M2025-06-13: 3.7M2025-06-30: 4.4M2025-07-15: 4.4M2025-07-31: 4.2M2025-08-15: 4.3M2025-08-29: 4.3M2025-09-15: 4.2M2025-09-30: 3.2M2025-10-15: 3.7M2025-10-31: 4.1M2025-11-14: 4.3M2025-11-28: 4.4M2025-12-15: 4.3M2025-12-31: 4.4M2026-01-15: 6.0M2026-01-30: 5.7M2026-02-13: 5.4M2026-02-27: 7.9M2026-03-13: 7.6M2026-03-31: 7.6M
    the 31 Mar 2026 report24 earlier reportsnormal: 4.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 2 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 2 Apr 2026Filings record

    Director or officer change

  10. 25 Mar 2026Short interest and volume change

    had 7.6M shares sold short in the 13 Mar 2026 report, 1.9× the same report last year.

    Same report last year: 4.1M; its normal report is 4.3M.

    See the evidence
    This period
    7.6M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    4.3M
    Typical spread (median absolute deviation)
    359K
    How far from its usual level
    +6.3
    Same report last year
    4.1M
    History used
    2,020 days
    2025-03-14: 4.1M2025-03-31: 3.5M2025-04-15: 3.3M2025-04-30: 3.2M2025-05-15: 2.6M2025-05-30: 3.4M2025-06-13: 3.7M2025-06-30: 4.4M2025-07-15: 4.4M2025-07-31: 4.2M2025-08-15: 4.3M2025-08-29: 4.3M2025-09-15: 4.2M2025-09-30: 3.2M2025-10-15: 3.7M2025-10-31: 4.1M2025-11-14: 4.3M2025-11-28: 4.4M2025-12-15: 4.3M2025-12-31: 4.4M2026-01-15: 6.0M2026-01-30: 5.7M2026-02-13: 5.4M2026-02-27: 7.9M2026-03-13: 7.6M
    the 13 Mar 2026 report24 earlier reportsnormal: 4.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 11 Mar 2026Short interest and volume change

    had 7.9M shares sold short in the 27 Feb 2026 report, 2.0× the same report last year.

    Same report last year: 3.9M; its normal report is 4.2M.

    See the evidence
    This period
    7.9M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    4.2M
    Typical spread (median absolute deviation)
    275K
    How far from its usual level
    +8.8
    Same report last year
    3.9M
    History used
    2,006 days
    2025-02-28: 3.9M2025-03-14: 4.1M2025-03-31: 3.5M2025-04-15: 3.3M2025-04-30: 3.2M2025-05-15: 2.6M2025-05-30: 3.4M2025-06-13: 3.7M2025-06-30: 4.4M2025-07-15: 4.4M2025-07-31: 4.2M2025-08-15: 4.3M2025-08-29: 4.3M2025-09-15: 4.2M2025-09-30: 3.2M2025-10-15: 3.7M2025-10-31: 4.1M2025-11-14: 4.3M2025-11-28: 4.4M2025-12-15: 4.3M2025-12-31: 4.4M2026-01-15: 6.0M2026-01-30: 5.7M2026-02-13: 5.4M2026-02-27: 7.9M
    the 27 Feb 2026 report24 earlier reportsnormal: 4.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 3 Feb 2026several at once

    reported $220K of lobbying spend for the quarter ended 31 Dec 2025, 1.5× the same quarter last year, while it had 6.0M shares sold short in the 15 Jan 2026 report, 1.1× the same report last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Lobbying: Lobbying spend jump became public on 20 Jan 2026

    Harmony Biosciences reported $220K of lobbying spend for the quarter ended 31 Dec 2025, 1.5× the same quarter last year.

    This period
    $220K (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $150K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +3.5
    Same quarter last year
    $150K
    History used
    3,928 days
    2023-12-31: $175K2024-03-31: $170K2024-06-30: $150K2024-09-30: $150K2024-12-31: $150K2025-03-31: $150K2025-06-30: $150K2025-09-30: $220K2025-12-31: $220K
    the quarter ended 31 Dec 20258 earlier quartersnormal: $150K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

    Short interest and volume: Short interest spike became public on 28 Jan 2026

    Harmony Biosciences had 6.0M shares sold short in the 15 Jan 2026 report, 1.1× the same report last year.

    This period
    6.0M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    4.1M
    Typical spread (median absolute deviation)
    324K
    How far from its usual level
    +3.9
    Same report last year
    5.5M
    History used
    1,963 days
    2025-01-15: 5.5M2025-01-31: 3.8M2025-02-14: 3.7M2025-02-28: 3.9M2025-03-14: 4.1M2025-03-31: 3.5M2025-04-15: 3.3M2025-04-30: 3.2M2025-05-15: 2.6M2025-05-30: 3.4M2025-06-13: 3.7M2025-06-30: 4.4M2025-07-15: 4.4M2025-07-31: 4.2M2025-08-15: 4.3M2025-08-29: 4.3M2025-09-15: 4.2M2025-09-30: 3.2M2025-10-15: 3.7M2025-10-31: 4.1M2025-11-14: 4.3M2025-11-28: 4.4M2025-12-15: 4.3M2025-12-31: 4.4M2026-01-15: 6.0M
    the 15 Jan 2026 report24 earlier reportsnormal: 4.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  13. 28 Jan 2026Short interest and volume change

    had 6.0M shares sold short in the 15 Jan 2026 report, 1.1× the same report last year.

    Same report last year: 5.5M; its normal report is 4.1M.

    See the evidence
    This period
    6.0M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    4.1M
    Typical spread (median absolute deviation)
    324K
    How far from its usual level
    +3.9
    Same report last year
    5.5M
    History used
    1,963 days
    2025-01-15: 5.5M2025-01-31: 3.8M2025-02-14: 3.7M2025-02-28: 3.9M2025-03-14: 4.1M2025-03-31: 3.5M2025-04-15: 3.3M2025-04-30: 3.2M2025-05-15: 2.6M2025-05-30: 3.4M2025-06-13: 3.7M2025-06-30: 4.4M2025-07-15: 4.4M2025-07-31: 4.2M2025-08-15: 4.3M2025-08-29: 4.3M2025-09-15: 4.2M2025-09-30: 3.2M2025-10-15: 3.7M2025-10-31: 4.1M2025-11-14: 4.3M2025-11-28: 4.4M2025-12-15: 4.3M2025-12-31: 4.4M2026-01-15: 6.0M
    the 15 Jan 2026 report24 earlier reportsnormal: 4.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 20 Jan 2026Lobbying change

    reported $220K of lobbying spend for the quarter ended 31 Dec 2025, 1.5× the same quarter last year.

    Same quarter last year: $150K; its normal quarter is $150K.

    See the evidence
    This period
    $220K (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $150K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +3.5
    Same quarter last year
    $150K
    History used
    3,928 days
    2023-12-31: $175K2024-03-31: $170K2024-06-30: $150K2024-09-30: $150K2024-12-31: $150K2025-03-31: $150K2025-06-30: $150K2025-09-30: $220K2025-12-31: $220K
    the quarter ended 31 Dec 20258 earlier quartersnormal: $150K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  15. 20 Jan 2026Lobbying record

    HARMONY BIOSCIENCES MANAGEMENT, INC.: lobbying engagement terminated (SCHAERR JAFFE LLP) (dated 31 Dec 2025)

  16. 25 Jul 2025Lobbying record

    HARMONY BIOSCIENCES MANAGEMENT, INC.: new lobbying registration (SCHAERR JAFFE LLP) (dated 1 Jul 2025)

  17. 16 Jul 2025Lobbying record

    HARMONY BIOSCIENCES: new lobbying registration (LMH STRATEGIC SOLUTIONS) (dated 1 Jul 2025)

  18. 3 Apr 2025Filings record

    Director or officer change

  19. 24 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 24 Mar 2025Filings record

    Director or officer change

  21. 9 Dec 2024Lobbying record

    HARMONY BIOSCIENCES: lobbying engagement terminated (WATKINS & EAGER PLLC) (dated 31 Oct 2024)

  22. 5 Dec 2024Lobbying record

    HARMONY BIOSCIENCES: new lobbying registration (HARPER & BAILEY GOVERNMENTAL SOLUTIONS LLC) (dated 1 Nov 2024)

  23. 1 Jul 2024Filings record

    Director or officer change

  24. 3 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  25. 3 May 2024Filings record

    Director or officer change

  26. 17 Apr 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['INS', 'MMM']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12614863
  27. 8 Apr 2024Lobbying record

    HARMONY BIOSCIENCES: lobbying engagement terminated (THORN RUN PARTNERS) (dated 31 Dec 2023)

  28. 19 Jan 2024Lobbying record

    HARMONY BIOSCIENCES, LLC: lobbying engagement terminated (RAMPY NORTHRUP LLC) (dated 31 Dec 2023)

  29. 12 Jan 2024Lobbying record

    HARMONY BIOSCIENCES: new lobbying registration (WATKINS & EAGER PLLC) (dated 1 Jan 2024)

  30. 8 Jan 2024Lobbying record

    ZYNERBA PHARMACEUTICALS, INC.: lobbying engagement terminated (WATKINS & EAGER PLLC) (dated 15 Oct 2023)

  31. 8 Nov 2023Filings record

    Director or officer change

  32. 11 Oct 2023Filings record

    Completed an acquisition or asset sale

  33. 5 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 5 Oct 2023Filings record

    Director or officer change

  35. 27 Jul 2023Filings record

    A major agreement ended

  36. 24 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 24 Apr 2023Filings record

    Director or officer change

  38. 23 Jan 2023Filings record

    Director or officer change

  39. 6 Jan 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 6 Jan 2023Filings record

    Director or officer change

Showing the newest 40 of 85 entries; narrow the window or the kind of data to see older ones.

Not listed: 163 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001802665
Ticker
HRMY
Domain
harmonybiosciences.com
Hq location
PA|PLYMOUTH MEETING|19462 (1 unverified)
Lobbying client
harmony biosciences, harmony biosciences management, zynerba pharmaceuticals
Name
Epygenix Therapeutics, Inc, Harmony Biosciences Holdings, Inc., Harmony Biosciences, LLC, Harmony Biosciences Management, Inc and 1 more
  • Federal lobbying disclosures (LDA)21 records, 134 data points1 Feb 2015 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 225 data points30 Sep 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)99 records27 Jul 2020 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)513 data points31 Dec 2018 to 2 Nov 2026
  • SEC Form 4 insider transactions92 records, 344 data points24 Aug 2020 to 18 Sep 2026
  • FINRA short interest (twice monthly)443 data points31 Aug 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3146 data points19 Aug 2020 to 20 Nov 2026